| 30th Dec 2020 12:00 pm |
RNS |
NMPA approval of Surufatinib in China for ep-NET |
| 29th Dec 2020 7:45 am |
RNS |
US NDA Rolling Submission of Surufatinib Initiated |
| 22nd Dec 2020 7:00 am |
RNS |
Chi-Med to Present at JPM |
| 15th Dec 2020 9:45 am |
RNS |
Grant of Share Options under Share Option Scheme |
| 30th Nov 2020 7:00 am |
RNS |
Total Voting Rights |
| 27th Nov 2020 7:00 am |
RNS |
Notification of Dilution of Voting Rights |
| 17th Nov 2020 7:00 am |
RNS |
US$100m Equity Investment by CPP Investments |
| 5th Nov 2020 9:00 am |
RNS |
Chi-Med to Present HMPL-689 Clinical Data at ASH |
| 30th Oct 2020 12:00 pm |
RNS |
Chi-Med to Attend Upcoming Conferences |
| 30th Oct 2020 7:00 am |
RNS |
Total Voting Rights |
| 30th Sep 2020 7:00 am |
RNS |
Total Voting Rights |
| 21st Sep 2020 7:00 am |
RNS |
Surufatinib Data at ESMO and in Lancet Oncology |
| 17th Sep 2020 11:45 am |
RNS |
Second Chinese NDA Acceptance for Surufatinib |
| 4th Sep 2020 7:00 am |
RNS |
Chi-Med Initiates Global Phase III Trial |
| 3rd Sep 2020 7:00 am |
RNS |
Chi-Med Initiates a Phase II Trial |
| 28th Aug 2020 11:30 am |
RNS |
Total Voting Rights |
| 24th Aug 2020 7:00 am |
RNS |
Clinical Data to be Presented at ESMO 2020 |
| 12th Aug 2020 10:30 am |
RNS |
Grant of Share Options under Share Option Scheme |
| 10th Aug 2020 7:00 am |
RNS |
Surufatinib Marketing Authorization Application |
| 30th Jul 2020 12:00 pm |
RNS |
Interim Results and Clinical Update |
| 30th Jul 2020 7:00 am |
RNS |
Block Admission Application |
| 28th Jul 2020 7:00 am |
RNS |
Chi-Med & Lilly Collaborate on Elunate in China |
| 28th Jul 2020 7:00 am |
RNS |
Savolitinib NDA Granted Priority Review in China |
| 24th Jul 2020 7:00 am |
RNS |
Chi-Med Initiates HMPL-306 Phase I Trial in China |
| 8th Jul 2020 8:00 am |
RNS |
Holding(s) in Company |
| 7th Jul 2020 8:00 am |
RNS |
Holding(s) in Company |
| 7th Jul 2020 7:00 am |
RNS |
Notification of Dilution of Voting Rights |
| 29th Jun 2020 7:00 am |
RNS |
Blocklisting Six Monthly Return |
| 26th Jun 2020 7:00 am |
RNS |
Notice of Results |
| 25th Jun 2020 7:15 am |
RNS |
$100 Million Equity Investment by General Atlantic |
| 18th Jun 2020 8:15 am |
RNS |
Fruquintinib Granted US FDA Fast Track Designation |
| 9th Jun 2020 7:00 am |
RNS |
US$95m Guangzhou Land Compensation Agreement |
| 4th Jun 2020 7:00 am |
RNS |
Continuation of Phase III FRUTIGA Study |
| 2nd Jun 2020 4:40 pm |
RNS |
Second Price Monitoring Extn |
| 2nd Jun 2020 4:37 pm |
RNS |
Price Monitoring Extension |
| 1st Jun 2020 7:00 am |
RNS |
Chi-Med Plans to Submit US NDA for Surufatinib |
| 29th May 2020 1:00 pm |
RNS |
Chi-Med to Discuss Data Presented at ASCO20 |
| 29th May 2020 7:00 am |
RNS |
NDA Acceptance in China for Savolitinib |
| 26th May 2020 7:00 am |
RNS |
Chi-Med and BeiGene Enter Clinical Collaboration |
| 14th May 2020 7:00 am |
RNS |
Clinical Data to be Presented at ASCO20 |
